Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus [Yahoo! Finance]
Is It Too Late To Reassess Praxis Precision Medicines (PRAX) After Its 1-Year Surge? [Yahoo! Finance]
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Wedbush from $83.00 to $95.00. They now have an "underperform" rating on the stock.
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress [Yahoo! Finance]